A Phase II, Randomized, Double-Blind, Placebo-and Active-Controlled, Multi-Center Study to Determine the Efficacy and Safety of TAK-379 in Subjects With Type 2 Diabetes.

Trial Profile

A Phase II, Randomized, Double-Blind, Placebo-and Active-Controlled, Multi-Center Study to Determine the Efficacy and Safety of TAK-379 in Subjects With Type 2 Diabetes.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jun 2013

At a glance

  • Drugs Pioglitazone; TAK 379
  • Indications Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 09 Jun 2010 Actual patient number (323) added as reported by ClinicalTrials.gov.
    • 21 Apr 2009 Status changed from recruiting to discontinued, as reported in a Takeda media release.
    • 13 Jan 2009 Official title amended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top